Ocuphire Announces the US Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

4/1/24 7:17:13 AM ET

$OCUP

$VTRS

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OCUP alert in real time by email

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ:VTRS).

Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine Ophthalmic Solution 0.75%. Under the terms of this agreement, Ocuphire is eligible to receive regulatory and commercial milestones as well as royalties.

Get the next $OCUP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OCUP
$VTRS

Company	Date	Price Target	Rating	Analyst
Viatris Inc. $VTRS	7/19/2024	$15.00	Buy	Jefferies
Viatris Inc. $VTRS	10/23/2023	$13.00 → $9.00	Neutral → Underperform	BofA Securities
Viatris Inc. $VTRS	6/23/2023	$11.00	Equal Weight → Underweight	Barclays
Viatris Inc. $VTRS	4/24/2023	$11.00	Overweight → Equal Weight	Barclays
Viatris Inc. $VTRS	2/17/2023	$16.00 → $14.00	Outperform → Market Perform	BMO Capital Markets
Viatris Inc. $VTRS	1/27/2023	$13.00 → $15.00	Hold → Buy	Jefferies
Viatris Inc. $VTRS	11/10/2022	$9.00 → $12.00	Sell → Neutral	UBS
Viatris Inc. $VTRS	11/8/2022	$10.00	Underweight → Neutral	Piper Sandler

More analyst ratings

$OCUP
$VTRS
Financials

Live finance-specific insights

Viatris Reports Third Quarter Financial Results for 2024
PITTSBURGH, Nov. 7, 2024 /PRNewswire/ -- Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1] Strong New Product Revenues of $133 Million Drove Growth Across Segments U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on a Divestiture-Adjusted Basis[2] Repaid ~$1.9 Billion of Debt, Expects to Achieve its Long-Term Gross Leverage Target of ~3.0x by end of the Year[3] Entered into Exclusive Licensing Agreement for
11/7/24 6:59:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Viatris Announces Third Quarter 2024 Dividend
PITTSBURGH, Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we p
11/5/24 6:59:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Ocuphire Pharma Announces Acquisition of Opus Genetics
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025 LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances remains on track for top-line data in Q1 2025 VEGA-3 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in presbyopia remains on track for top-line data in H1 2025 Company will seek a strategic partner to continue development of
10/22/24 4:05:00 PM ET
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care

Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors
PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit
6/3/24 6:59:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas. Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology
4/15/24 8:00:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP) ("Ocuphire"), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today. George Magrath, M.D. M.B.A, M.S. CEO commented, "As the biology of Ref-
2/14/24 8:00:00 AM ET
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care

Viatris Reports Third Quarter Financial Results for 2024
PITTSBURGH, Nov. 7, 2024 /PRNewswire/ -- Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1] Strong New Product Revenues of $133 Million Drove Growth Across Segments U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on a Divestiture-Adjusted Basis[2] Repaid ~$1.9 Billion of Debt, Expects to Achieve its Long-Term Gross Leverage Target of ~3.0x by end of the Year[3] Entered into Exclusive Licensing Agreement for
11/7/24 6:59:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Viatris Announces Third Quarter 2024 Dividend
PITTSBURGH, Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we p
11/5/24 6:59:00 AM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care
Viatris Named to Forbes' World's Top Companies for Women 2024 List
PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. "At Viatris, diverse perspectives drive innovation and our ability to make an impact, as we empower people worldwide to live healthier at every stage of life," said Andrew Enrietti, Chief People Officer, Viatris. "Being recognized on Forbes' list of the World's Top Companies for Women 2024 demonstrates our focus on investing in our people and fostering diverse talent. This accolade
10/29/24 12:00:00 PM ET
$VTRS
Biotechnology: Pharmaceutical Preparations
Health Care

Ocuphire Announces the US Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

Chat with this insight

Recent Analyst Ratings for $OCUP$VTRS

$OCUP$VTRS Financials

Live finance-specific insights

Viatris Reports Third Quarter Financial Results for 2024

Viatris Announces Third Quarter 2024 Dividend

Ocuphire Pharma Announces Acquisition of Opus Genetics

$OCUP$VTRS FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for RYZUMVI issued to OCUPHIRE PHARMA INC

$OCUP$VTRS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Viatris Inc.

SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

SEC Form SC 13G filed by Viatris Inc.

$OCUP$VTRS Leadership Updates

Live Leadership Updates

$OCUP$VTRS Press Releases

Fastest customizable press release news feed in the world

$OCUP$VTRS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

Viatris Reports Third Quarter Financial Results for 2024

Viatris Announces Third Quarter 2024 Dividend

Viatris Named to Forbes' World's Top Companies for Women 2024 List

Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

Jayagopal Ashwath bought $6,178 worth of shares (3,500 units at $1.76), increasing direct ownership by 5% to 78,500 units (SEC Form 4)

Magrath George bought $8,772 worth of shares (5,000 units at $1.75), increasing direct ownership by 1% to 430,000 units (SEC Form 4)

$OCUP$VTRS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Officer Campbell Paul sold $346,686 worth of shares (26,925 units at $12.88), decreasing direct ownership by 18% to 126,901 units (SEC Form 4)

Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

SEC Form 4 filed by Director Graves Adrienne L

$OCUP$VTRS SEC Filings

SEC Form 144 filed by Viatris Inc.

SEC Form 10-Q filed by Viatris Inc.

Viatris Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

$OCUP$VTRS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies resumed coverage on Viatris with a new price target

Viatris downgraded by BofA Securities with a new price target

Viatris downgraded by Barclays with a new price target

$OCUP$VTRS Market Insights

Live Market Insights

Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?

Jefferies Reinstates Buy on Viatris, Announces $15 Price Target

Ocuphire Pharma Participates In ARVO SIG Panel And ASRS 42nd Annual Scientific Meeting To Highlight APX3330 For Diabetic Retinopathy

Recent Analyst Ratings for
$OCUP
$VTRS

$OCUP
$VTRS
Financials

$OCUP
$VTRS
FDA approvals

$OCUP
$VTRS
Large Ownership Changes

$OCUP
$VTRS
Leadership Updates

$OCUP
$VTRS
Press Releases

$OCUP
$VTRS
Insider Purchases

$OCUP
$VTRS
Insider Trading

$OCUP
$VTRS
SEC Filings

$OCUP
$VTRS
Analyst Ratings

$OCUP
$VTRS
Market Insights